FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367602020> ?p ?o ?g. }

• W4367602020 endingPage "2815" @default.
• W4367602020 startingPage "2808" @default.
• W4367602020 abstract "Abstract Purpose: Patients with platinum-resistant ovarian cancer respond poorly to existing therapies. Hence there is a need for more effective treatments. Patients and Methods: The DeCidE1 trial is a multicenter, randomized, open-label, single-arm phase II study to evaluate the safety and effectiveness of maveropepimut-S with cyclophosphamide in patients with recurrent ovarian cancer. Median follow-up for evaluable subjects was 4.4 months. Data were collected from March 2019 to June 2021. Subjects received two injections of 0.25 mL maveropepimut-S 3 weeks apart, followed by one 0.1-mL doses, every 8 weeks up to progression. Oral cyclophosphamide, 50 mg twice daily, was administered in repeating weekly on and off cycles. Results: Twenty-two patients were enrolled. Median age was 58 years (38–78 years). Among the evaluable population, the objective response rate (ORR) was 21% [90% confidence interval (CI), 7.5%–41.9%], with a disease control rate (DCR) of 63% (90% CI, 41.8%–81.3%), including 4 (21%) patients with partial responses, 8 (42%) stable disease, and 7 (37%) progressive disease. The ORRs were consistent across subgroups based on platinum sensitivity, and DCR was higher in the platinum-resistant subpopulation. Four SD patients maintained clinical benefit up to 25 months. Most treatment-related adverse events (TRAE) were grade 1 and 2 (87% of unique events). Most common AEs were injection site reactions. Eight subjects reported grade 3 and no grade 4 AEs. Survivin-specific T-cell responses were observed in treated patients with clinical benefit. Conclusions: Maveropepimut-S with intermittent low-dose cyclophosphamide is well-tolerated, with clinical benefit for patients with recurrent ovarian cancer. Observed responses are irrespective of the platinum status." @default.
• W4367602020 created "2023-05-02" @default.
• W4367602020 creator A5013343735 @default.
• W4367602020 creator A5018001559 @default.
• W4367602020 creator A5020493456 @default.
• W4367602020 creator A5033635354 @default.
• W4367602020 creator A5035803590 @default.
• W4367602020 creator A5038190564 @default.
• W4367602020 creator A5044874564 @default.
• W4367602020 creator A5049011165 @default.
• W4367602020 creator A5061125828 @default.
• W4367602020 creator A5062800449 @default.
• W4367602020 creator A5069625939 @default.
• W4367602020 creator A5071412396 @default.
• W4367602020 creator A5074884103 @default.
• W4367602020 creator A5075958765 @default.
• W4367602020 date "2023-05-01" @default.
• W4367602020 modified "2023-10-12" @default.
• W4367602020 title "Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial" @default.
• W4367602020 cites W104750606 @default.
• W4367602020 cites W1523461418 @default.
• W4367602020 cites W1540060031 @default.
• W4367602020 cites W1602732985 @default.
• W4367602020 cites W1918156452 @default.
• W4367602020 cites W1968525251 @default.
• W4367602020 cites W1973091654 @default.
• W4367602020 cites W1990675339 @default.
• W4367602020 cites W2002710053 @default.
• W4367602020 cites W2012505533 @default.
• W4367602020 cites W2024039874 @default.
• W4367602020 cites W2041056208 @default.
• W4367602020 cites W2072059383 @default.
• W4367602020 cites W2078852869 @default.
• W4367602020 cites W2080943490 @default.
• W4367602020 cites W2108177250 @default.
• W4367602020 cites W2119478570 @default.
• W4367602020 cites W2137074525 @default.
• W4367602020 cites W2147622445 @default.
• W4367602020 cites W2150663100 @default.
• W4367602020 cites W2168920981 @default.
• W4367602020 cites W2296049142 @default.
• W4367602020 cites W2309852721 @default.
• W4367602020 cites W2345394027 @default.
• W4367602020 cites W2396289154 @default.
• W4367602020 cites W2527905628 @default.
• W4367602020 cites W2572174216 @default.
• W4367602020 cites W2624915196 @default.
• W4367602020 cites W2781863615 @default.
• W4367602020 cites W2788656587 @default.
• W4367602020 cites W2792511820 @default.
• W4367602020 cites W2797967795 @default.
• W4367602020 cites W2802155618 @default.
• W4367602020 cites W2804711363 @default.
• W4367602020 cites W2890261294 @default.
• W4367602020 cites W2911940503 @default.
• W4367602020 cites W2972524777 @default.
• W4367602020 cites W3004954919 @default.
• W4367602020 cites W3033443551 @default.
• W4367602020 cites W3092122627 @default.
• W4367602020 cites W3094922645 @default.
• W4367602020 cites W3095487872 @default.
• W4367602020 cites W3105357800 @default.
• W4367602020 cites W3108804421 @default.
• W4367602020 cites W3128646645 @default.
• W4367602020 cites W3162975920 @default.
• W4367602020 cites W3214232282 @default.
• W4367602020 doi "https://doi.org/10.1158/1078-0432.ccr-22-2595" @default.
• W4367602020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37126016" @default.
• W4367602020 hasPublicationYear "2023" @default.
• W4367602020 type Work @default.
• W4367602020 citedByCount "1" @default.
• W4367602020 crossrefType "journal-article" @default.
• W4367602020 hasAuthorship W4367602020A5013343735 @default.
• W4367602020 hasAuthorship W4367602020A5018001559 @default.
• W4367602020 hasAuthorship W4367602020A5020493456 @default.
• W4367602020 hasAuthorship W4367602020A5033635354 @default.
• W4367602020 hasAuthorship W4367602020A5035803590 @default.
• W4367602020 hasAuthorship W4367602020A5038190564 @default.
• W4367602020 hasAuthorship W4367602020A5044874564 @default.
• W4367602020 hasAuthorship W4367602020A5049011165 @default.
• W4367602020 hasAuthorship W4367602020A5061125828 @default.
• W4367602020 hasAuthorship W4367602020A5062800449 @default.
• W4367602020 hasAuthorship W4367602020A5069625939 @default.
• W4367602020 hasAuthorship W4367602020A5071412396 @default.
• W4367602020 hasAuthorship W4367602020A5074884103 @default.
• W4367602020 hasAuthorship W4367602020A5075958765 @default.
• W4367602020 hasBestOaLocation W43676020201 @default.
• W4367602020 hasConcept C121608353 @default.
• W4367602020 hasConcept C126322002 @default.
• W4367602020 hasConcept C141071460 @default.
• W4367602020 hasConcept C168563851 @default.
• W4367602020 hasConcept C197934379 @default.
• W4367602020 hasConcept C2776694085 @default.
• W4367602020 hasConcept C2776755627 @default.
• W4367602020 hasConcept C2778822529 @default.
• W4367602020 hasConcept C2780427987 @default.
• W4367602020 hasConcept C2908647359 @default.
• W4367602020 hasConcept C31760486 @default.

• next